Covered recipient · General Payments record
FARHAN MOHAMMAD
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$4,059.80
- Reported across 198 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,277.01 | 57 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $163.12 | 8 |
| Acerta Pharma LLC | $162.15 | 6 |
| Daiichi Sankyo Inc. | $75.34 | 3 |
| Janssen Biotech, Inc. | $69.09 | 3 |
| Sirtex Medical Inc | $61.45 | 2 |
| Medtronic, Inc. | $58.19 | 3 |
| Inari Medical, Inc. | $54.37 | 2 |
| Pharmacosmos Therapeutics Inc. | $51.93 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $51.60 | 3 |
| Incyte Corporation | $49.99 | 2 |
| ARRAY BIOPHARMA INC | $44.73 | 2 |
| Alnylam Pharmaceuticals Inc. | $44.55 | 2 |
| Gilead Sciences, Inc. | $38.07 | 2 |
| E.R. Squibb & Sons, L.L.C. | $36.79 | 2 |
| GENZYME CORPORATION | $35.58 | 1 |
| Rigel Pharmaceuticals, Inc. | $27.55 | 1 |
| Kite Pharma, Inc. | $24.86 | 1 |
| Genmab U.S., Inc. | $23.32 | 1 |
| Merck Sharp & Dohme Corporation | $22.81 | 1 |
| Kyowa Kirin, Inc. | $21.34 | 1 |
| ABBVIE INC. | $21.15 | 1 |
| SECURA BIO, INC. | $20.32 | 1 |
| Astellas Pharma US Inc | $19.32 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.36 | 1 |
| GlaxoSmithKline, LLC. | $17.86 | 1 |
| Janssen Pharmaceuticals, Inc | $16.61 | 1 |
| ADC Therapeutics America, Inc. | $15.86 | 1 |
| Celgene Corporation | $15.48 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $15.22 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (57)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.